Share on StockTwits

Abbott Laboratories (NYSE:ABT) is set to post its Q214 quarterly earnings results on Wednesday, July 16th. Analysts expect Abbott Laboratories to post earnings of $0.51 per share and revenue of $5.53 billion for the quarter. Abbott Laboratories has set its FY14 guidance at $2.16-2.26 EPS.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, April 16th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.05. The company had revenue of $5.24 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the previous year, the company posted $0.42 earnings per share. The company’s revenue for the quarter was down 2.5% on a year-over-year basis. On average, analysts expect Abbott Laboratories to post $2.19 EPS for the current fiscal year and $2.44 EPS for the next fiscal year.

Shares of Abbott Laboratories (NYSE:ABT) opened at 41.82 on Tuesday. Abbott Laboratories has a one year low of $32.70 and a one year high of $41.96. The stock has a 50-day moving average of $40.51 and a 200-day moving average of $39.0. The company has a market cap of $62.811 billion and a P/E ratio of 27.01.

The company also recently announced a quarterly dividend, which is scheduled for Friday, August 15th. Shareholders of record on Tuesday, July 15th will be paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 2.10%. The ex-dividend date is Friday, July 11th.

A number of analysts have recently weighed in on ABT shares. Analysts at Jefferies Group reiterated a “buy” rating on shares of Abbott Laboratories in a research note on Monday. They now have a $52.00 price target on the stock, up previously from $49.00. On the ratings front, analysts at Morgan Stanley reiterated a “neutral” rating on shares of Abbott Laboratories in a research note on Thursday, July 10th. They now have a $46.00 price target on the stock, up previously from $39.00. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Abbott Laboratories in a research note on Friday, May 30th. They now have a $42.00 price target on the stock. Two research analysts have rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $41.55.

Abbott Laboratories (NYSE:ABT) is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.